(Press-News.org) A new technique designed to allow surgeons to identify and remove residual tumor tissue during breast-conserving surgery showed promising results in a multi-center trial led by investigators from the Mass General Cancer Center, a member of Mass General Brigham. The clinical trial, which was funded in part by Lumicell, Inc., evaluated Lumicell’s investigational optical imaging agent pegulicianine in fluorescence-guided surgery (pFGS). In pFGS, pegulicianine is activated to a fluorescent form at sites of residual tumor, allowing surgeons to identify tumor remaining in the surgical site during breast cancer surgery. Investigators found that pFGS enabled removal of residual tumor cells left behind by standard lumpectomy procedures or avoided second surgeries in 10 percent of study patients. Results are published in NEJM Evidence.
“The goal of our research is to evaluate ways to improve the effectiveness of lumpectomy surgery, reduce the burden on patients and to help surgeons get to clean margins,” said corresponding author Barbara Smith, MD, PhD, the director of the Breast Program at Mass General Cancer Center and head of the Breast Section in the Department of Surgery. “In our study, this intervention had a favorable effect for 10 percent of the patients that we studied. By evaluating margins in real time, surgeons can remove additional tissue immediately.”
Traditionally, tumor margins are evaluated by pathologists after the tumor has been removed from the patient’s cavity by surgeons. Tumor specimens are often deformed after they have been excised, making it challenging to evaluate margin orientation, and the return of results can take several days. The pFGS approach involves injecting pegulicianine, a fluorescent dye, prior to surgery. After surgeons remove the initial tumor specimen, they use a hand-held probe to scan the lumpectomy cavity looking for additional tumor to remove. Image analysis software then displays any fluorescent signal on a screen, indicating remaining tumor tissue for removal.
To evaluate pFGS, Smith and colleagues conducted a prospective trial, enrolling 406 patients at 14 U.S. sites. All patients were undergoing lumpectomy for stages 1 to 3 invasive breast cancer and/or ductal in situ carcinoma (considered the earliest form of breast cancer). Among patients who were randomized to receive pFGS, surgeons performed their standard lumpectomy and then removed additional tissue based on pFGS guidance.
In 27 of 357 patients (7.6 percent) who underwent pFGS, the technique detected tumor tissue that had been left behind by standard lumpectomy. In the 17 percent of patients who had positive margins after standard surgery, 9 of 62 had all margins cleared by pFGS, potentially avoiding a second surgical procedure. pFGS had few safety events—the rate of allergic reactions was low and similar to that of other commonly used imaging agents.
The team also assessed diagnostic performance of pFGS by measuring the percentage of margins with tumor that were pFGS positive (sensitivity) and the percentage of margins with no tumor that were pFGS negative (specificity). Sensitivity was 49.3 percent across all study margins, and 58.6 percent for margins where direct histopathology comparison was available. Specificity was 85.2 percent.
“These results compare favorably with standard-of-care margin assessment,” said Smith.
The trial met prespecified thresholds for removal of residual tumor and specificity but did not meet its prespecified sensitivity goal, which may be due to the trial’s design, which did not include taking additional margin specimens when there were negative pFGS readings. Smith and colleagues are involved in ongoing studies that will obtain additional margin tissue to calculate sensitivity more precisely. They will also look in greater detail at how effectively pFGS clears margins, comparing outcomes to standard surgery and rates of recurrence.
“Overall, we found that pFGS removed tumor missed by standard lumpectomy and reduced the need for second surgeries for positive margins,” said Smith. “Given its potential, pFGS merits evaluation in future trials and studies.”
Disclosures: Author disclosures and other supplementary materials are available at evidence.nejm.org.
Funding: Supported by Lumicell, Inc. and the National Institutes of Health (grant number 1R44CA211013-01).
Paper cited: Smith BL et al. “Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery” NEJM Evidence DOI: 10.1056/EVIDoa2200333
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds in medicine to make life-changing impact for patients in our communities and people around the world.
Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services.
Mass General Brigham is a non-profit organization that is committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. For more information, please visit massgeneralbrigham.org.
END
New York, NY, 3 May 2023 - Today, Eric and Wendy Schmidt announced the members of the 2023 cohort of Schmidt Science Fellows. The 32 exceptional early career scientists will receive support to develop research projects and the leadership skills necessary to harness interdisciplinary science to tackle some of the world’s most intractable problems.
Schmidt Science Fellows is the inaugural program of Schmidt Futures, the philanthropic initiative of Eric and Wendy Schmidt with a mission to find and connect talented people to solve our world’s hardest ...
Researchers from Duke University, University of Notre Dame, and Microsoft published a new Journal of Marketing article that examines using “true normal prices” during a sale as a way to reduce deceptive pricing tricks.
The study, forthcoming in the Journal of Marketing, is titled “Competition and the Regulation of Fictitious Pricing” and is authored by Richard Staelin, Joel E. Urbany, and Donald Ngwe.
Does competition make firms more honest? Over 50 years ago, the Federal Trade Commission (FTC) assumed the answer was yes when it stopped enforcing ...
Using ESO’s Very Large Telescope (VLT), researchers have found for the first time the fingerprints left by the explosion of the first stars in the Universe. They detected three distant gas clouds whose chemical composition matches what we expect from the first stellar explosions. These findings bring us one step closer to understanding the nature of the first stars that formed after the Big Bang.
“For the first time ever, we were able to identify the chemical traces of the explosions of the first stars in very distant ...
A new study shows that sleep spindles, brief bursts of brain activity occurring during one phase of sleep and captured by EEG, may regulate anxiety in people with post-traumatic stress disorder (PTSD).
The study shines a light on the role of spindles in alleviating anxiety in PTSD as well as confirms their established role in the transfer of new information to longer-term memory storage. The findings challenge recent work by other researchers that has indicated spindles may heighten intrusive and violent thoughts in people with PTSD.
The final draft of the preprint publishes in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging on ...
KANSAS CITY, MO—May 3, 2023—The Stowers Institute for Medical Research announced the hiring of three principal investigators to further expand its team of scientists who seek to answer life’s biggest mysteries through foundational research. Siva Sankari, Ph.D., from Massachusetts Institute for Technology, Neşet Özel, Ph.D., from New York University, and Ameya Mashruwala, Ph.D., from Princeton University, will join the Institute’s current team of 17 principal investigators and staff of 500. The addition of these scientists ...
ROCKVILLE, MD – The Biophysical Society is pleased to announce that Padmini Rangamani of the University of California, San Diego has been named as the new Editor-in-Chief of the The Biophysicsist, the Society’s open access education journal. The journal was developed under the leadership and vision of founding and current Editor-in-Chief, Sam Safran of the Weizmann Institute of Science in Rehovot, Israel, to highlight and nurture biophysics education and its scholarship and development.
“Now, more than ever, is the time for an education journal such as The Biophysicist to steer the ...
VANCOUVER, Wash. – Women researchers received substantially less funding in grant awards than men—an average of about $342,000 compared to men’s $659,000, according to a large meta-analysis of studies on the topic.
Women were also less likely to receive second grants to continue their research. In first-time grant applications, proportional numbers of women and men scientists were approved for funding, but for re-applications, 9% fewer women who applied were approved than their male ...
In 2016, Oregon became the first state to adopt and implement an Automatic Voter Registration (AVR) system. Now, twenty-two states, plus Washington D.C., have such systems in place. Early research on the impacts of this innovation has shown an increase in the number of people registered, and greater diversity among the registrants.
Now, a researcher using Oregon voter data has identified an unintended consequence of Automatic Voter Registration: a steep drop in party registration. These results have been published in the journal Electoral Studies ...
PRESS RELEASE: PRINCESS MÁXIMA CENTER FOR PEDIATRIC ONCOLOGY
EMBARGO: WEDNESDAY 3 MAY 2023 AT 10:00AM BST (11:00AM CEST)
Scientists of the Princess Máxima Center for pediatric oncology and Hubrecht Institute in the Netherlands have revealed new scientific insights into the features of fibrolamellar carcinoma (FLC), a rare type of childhood liver cancer. Their findings, published today in Nature Communications, may help in developing new drug therapies in the future. Mini organs and the ‘molecular scissor’ system CRISPR-Cas9, allowed the researchers to better understand tumor biology and biological ...
Short-terms clinical trials have demonstrated the health benefits of low-carbohydrate diets (LCDs) and low-fat diets (LFDs) for weight loss and heart protection. Now a study published in the Journal of Internal Medicine looks at the effects of these diets on mortality in middle-aged and older adults.
In the study of 371,159 individuals aged 50 to 71 years, 165,698 deaths occurred over a median follow-up of 23.5 years.
A healthy LFD—characterized by low intake of saturated fat and high intakes of plant protein and high-quality carbohydrates—was related to fewer deaths from all causes, from cardiovascular diseases, and from cancers. In ...
